Press Releases

December 2, 2021

PROMIS NEUROSCIENCES SHAREHOLDERS APPROVE SPECIAL RESOLUTION

November 17, 2021

A SECOND INDEPENDENT PROXY ADVISOR, ISS, RECOMMENDS PROMIS NEUROSCIENCES SHAREHOLDERS VOTE FOR THE SHARE CONSOLIDATION 

Press Archives

In the News

October 5, 2021

Illawarra researchers awarded close to $1.5 million from FightMND. Professor Justin Yerbury awarded Drug Development Grant for his latest gene therapy research in collaboration with ProMIS Neurosciences that targets misfolded proteins associated with familial MND

News Archives

Podcasts

Presentations

September 13, 2021

H.C. Wainwright and Co. 23rd Annual Investment Conference

August 2, 2021

ProMIS Neurosciences Presentations at 2021 Alzheimer’s Association International Conference 

Presentations Archives

Videos

September 13, 2021

H.C. Wainwright and Co. 23rd Annual Investment Conference

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

August 6, 2019

Dr. James Kupiec’s update from AAIC 2019: Demonstrating Early Proof-of-Concept with Biomarkers and Focused Patient Populations

Video Archives